
Precision Biosciences (DTIL) Stock Forecast & Price Target
Precision Biosciences (DTIL) Analyst Ratings
Bulls say
Precision BioSciences Inc. is witnessing encouraging developments in its product pipeline, particularly with the PBGENE-HBV program, which may enhance the credibility of its ARCUS platform and de-risk its broader pipeline. Initial promising clinical data from the ECUR-506 trial indicates preliminary validation of in vivo ARCUS editing and suggests a positive safety profile, potentially benefiting further gene editing initiatives. Additionally, the favorable risk/reward outlook is supported by strong preclinical results and the company’s current valuation, which is substantially below its net cash position, providing a solid foundation for future growth opportunities.
Bears say
Precision BioSciences Inc. faces significant financial risks that contribute to a negative outlook on its stock. The company operates in a nascent gene editing sector, where regulatory hurdles and lengthy clinical trial processes could hinder product development timelines and impede potential revenue generation. Furthermore, reliance on intellectual property poses challenges, as litigation or competition may adversely affect its innovation pipeline and market positioning, compounding the risks of lower-than-expected sales impacting the company's financial performance.
This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Precision Biosciences (DTIL) Analyst Forecast & Price Prediction
Start investing in Precision Biosciences (DTIL)
Order type
Buy in
Order amount
Est. shares
0 shares